| Identification | Back Directory | [Name]
ABBV-075 | [CAS]
1445993-26-9 | [Synonyms]
5100
CS-2213
CS-2464
Mivibus
ABBV-075
Mivebresib
Mivebresib (ABBV-075 )
ABBV-075; ABBV075; ABBV 075
Mivebresib (ABBV075, ABBV-075, ABBV 075)
N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide
Ethanesulfonamide, N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]- | [Molecular Formula]
C22H19F2N3O4S | [MDL Number]
MFCD30377200 | [MOL File]
1445993-26-9.mol | [Molecular Weight]
459.47 |
| Chemical Properties | Back Directory | [Boiling point ]
608.9±65.0 °C(Predicted) | [density ]
1.465±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:60.0(Max Conc. mg/mL);130.59(Max Conc. mM) | [form ]
A crystalline solid | [pka]
8.37±0.10(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3 | [InChIKey]
RDONXGFGWSSFMY-UHFFFAOYSA-N | [SMILES]
C(S(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C2=CN(C)C(=O)C3NC=CC=32)=C1)(=O)=O)C |
| Hazard Information | Back Directory | [Uses]
ABBV 075-d5 is a deuterium labelled ABBV 075 (A215280), which is used for selective inhibition of the BD2 bromodomain of bromodomain and extra-??terminal proteins in prostate cancer. | [Biological Activity]
Mivebresib (ABBV-075) is a novel BET family bromodomain inhibitor. Binds to the bromodomain of BRD2/4/T with similar affinity (Ki values between 1-2.2 nM) with high selectivity. Low potency against BRD3 (Ki=12.2 nM) and moderate activity against CREBBP (Ki=87 μM). It can effectively trigger apoptosis in a variety of tumor cells. | [in vitro]
ABBV-075 has potent and potent single-agent activity in a variety of cancer cell lines (from solid tumors, leukemias and lymphomas) in cell viability assays. It is capable of disrupting cell cycle control, leading to G1 arrest, further senescence, inhibition of tumor formation, induction of apoptosis, and possibly targeting the tumor microenvironment to further provide better efficacy. | [in vivo]
In mouse models laterally xenografted with non-small cell and small cell lung cancer, pancreatic cancer, breast cancer, prostate cancer, head and neck cancer, multiple lymphomas, diffuse giant B-cell lymphoma, and leukemia, ABBV -075 has equal or better efficacy than other standard care agents. | [target]
| Target | Value | | BRD2 | | BRD4 | | BRD-T |
| [storage]
Store at -20°C |
|
| Company Name: |
Cck Pharmchem Co.,Ltd
|
| Telephone: |
0512-68131995 13862051930 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList19949/0_EN.htm |
|